DK3692015T3 - Hidtil ukendte glutaminantagonister og anvendelser deraf - Google Patents
Hidtil ukendte glutaminantagonister og anvendelser deraf Download PDFInfo
- Publication number
- DK3692015T3 DK3692015T3 DK18864999.0T DK18864999T DK3692015T3 DK 3692015 T3 DK3692015 T3 DK 3692015T3 DK 18864999 T DK18864999 T DK 18864999T DK 3692015 T3 DK3692015 T3 DK 3692015T3
- Authority
- DK
- Denmark
- Prior art keywords
- previously unknown
- glutamine antagonists
- antagonists
- glutamine
- unknown
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
- C07C245/18—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569118P | 2017-10-06 | 2017-10-06 | |
| US201862728214P | 2018-09-07 | 2018-09-07 | |
| PCT/US2018/054581 WO2019071110A1 (en) | 2017-10-06 | 2018-10-05 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3692015T3 true DK3692015T3 (da) | 2022-11-21 |
Family
ID=65994832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18864999.0T DK3692015T3 (da) | 2017-10-06 | 2018-10-05 | Hidtil ukendte glutaminantagonister og anvendelser deraf |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12195419B2 (da) |
| EP (1) | EP3692015B1 (da) |
| JP (1) | JP7358342B2 (da) |
| CN (1) | CN111566083A (da) |
| DK (1) | DK3692015T3 (da) |
| ES (1) | ES2930258T3 (da) |
| WO (1) | WO2019071110A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11185534B2 (en) | 2017-02-01 | 2021-11-30 | The Johns Hopkins University | Prodrugs of glutamine analogs |
| US20210177841A1 (en) * | 2017-11-03 | 2021-06-17 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
| JP7574198B2 (ja) * | 2019-01-18 | 2024-10-28 | ドラセン ファーマシューティカルズ インコーポレイテッド | Donプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
| JP2022519574A (ja) | 2019-02-11 | 2022-03-24 | ドラセン ファーマシューティカルズ インコーポレイテッド | L-グルタミン酸からdonプロドラッグを調製する方法 |
| KR20210151056A (ko) | 2019-02-11 | 2021-12-13 | 드라센 파마슈티컬스, 인코포레이티드 | L-피로글루탐산으로부터 don 전구약물을 제조하는 방법 |
| EP3942038A4 (en) * | 2019-03-18 | 2022-12-21 | Alteron Therapeutics, Inc. | MODULATORS OF TDP-43 |
| WO2021239049A1 (en) * | 2020-05-27 | 2021-12-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| WO2022078462A1 (en) * | 2020-10-15 | 2022-04-21 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| AU2021361970A1 (en) * | 2020-10-15 | 2023-06-15 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| JP2025078888A (ja) * | 2022-01-28 | 2025-05-21 | 国立大学法人富山大学 | グルタミナーゼ阻害剤 |
| WO2023202651A1 (en) * | 2022-04-21 | 2023-10-26 | Jacobio Pharmaceuticals Co., Ltd. | Polymorphic forms of glutamine antagonist and uses thereof |
| JP2025540593A (ja) * | 2022-11-02 | 2025-12-16 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 優先的な腫瘍への送達を伴うアゾトマイシンプロドラッグ |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158976A (en) * | 1990-10-29 | 1992-10-27 | The Children's Medical Center Corporation | Controlling glutamine/glutamate related neuronal injury |
| WO2007001395A2 (en) * | 2004-10-04 | 2007-01-04 | University Of South Carolina | Prevention and treatment of influenza with glutamine antagonist agents |
| US7585996B2 (en) | 2006-09-15 | 2009-09-08 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| WO2009029729A1 (en) | 2007-08-31 | 2009-03-05 | Genelabs Technologies, Inc. | Amino tricyclic-nucleoside compounds, compositions, and methods of use |
| CN108135872A (zh) | 2015-07-31 | 2018-06-08 | 约翰霍普金斯大学 | 用于治疗认知缺陷的谷氨酰胺拮抗剂 |
| CN108135875B (zh) | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | 用于治疗代谢重编程病症的方法和组合物 |
| EA034571B1 (ru) * | 2015-07-31 | 2020-02-21 | Дзе Джонс Хопкинс Юниверсити | Пролекарства аналогов глутамина |
| US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
| WO2017100558A1 (en) | 2015-12-09 | 2017-06-15 | Research Triangle Institute | Improved apelin receptor (apj) agonists and uses thereof |
| US11185534B2 (en) | 2017-02-01 | 2021-11-30 | The Johns Hopkins University | Prodrugs of glutamine analogs |
-
2018
- 2018-10-05 EP EP18864999.0A patent/EP3692015B1/en active Active
- 2018-10-05 DK DK18864999.0T patent/DK3692015T3/da active
- 2018-10-05 JP JP2020519241A patent/JP7358342B2/ja active Active
- 2018-10-05 CN CN201880079030.2A patent/CN111566083A/zh active Pending
- 2018-10-05 US US16/754,053 patent/US12195419B2/en active Active
- 2018-10-05 WO PCT/US2018/054581 patent/WO2019071110A1/en not_active Ceased
- 2018-10-05 ES ES18864999T patent/ES2930258T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020536867A (ja) | 2020-12-17 |
| ES2930258T3 (es) | 2022-12-09 |
| US12195419B2 (en) | 2025-01-14 |
| CN111566083A (zh) | 2020-08-21 |
| US20230009398A1 (en) | 2023-01-12 |
| JP7358342B2 (ja) | 2023-10-10 |
| EP3692015A4 (en) | 2021-06-30 |
| EP3692015B1 (en) | 2022-08-24 |
| EP3692015A1 (en) | 2020-08-12 |
| WO2019071110A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3692015T3 (da) | Hidtil ukendte glutaminantagonister og anvendelser deraf | |
| DK3596053T3 (da) | Farnesoid-x-receptoragonister og anvendelser deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3625263T3 (da) | Anti-galectin- 9-antistoffer og anvendelser deraf | |
| DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3609888T3 (da) | Farnesoid x-receptor-agonister og anvendelser deraf | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| DK3497094T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3350165T3 (da) | Farnesoid-X-receptoragonister og anvendelser deraf | |
| HRP20260151T1 (hr) | Modificirani polipeptidi i njihova uporaba | |
| DK3551221T3 (da) | Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf | |
| DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
| DK3655401T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| PL3268470T3 (pl) | Polipeptydy transpozazy i ich zastosowania | |
| DK3264955T3 (da) | Blandeanordning og fremgangsmåde | |
| DK3596125T3 (da) | Anti-PAR2-antistoffer og anvendelser deraf | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| DK3402821T5 (da) | Psma-bindende antistof og anvendelser deraf | |
| DK3494119T3 (da) | Forbindelser og sammensætninger og anvendelser deraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf |